Natco Pharma Ltd

- Currently, Natco Pharma does not plan to raise any capital through debt or equity as they have sufficient cash reserves. - The management is not a big fan of debt but will make judgment calls closer to the time if acquisition opportunities arise. - For large acquisitions, the company may consider a mix of cash, debt, and equity financing. - Presently, no capital raising is planned, but if a large transaction occurs, Natco Pharma is open to changing this stance. - The focus is on preserving cash for potential large acquisitions similar to Adcock Ingram. - Actively pursuing 2-3 acquisition targets with hopes to close at least 1 or 2 deals in 2025 or 2026, subject to clearances. (Source: Page 10 and Page 11 of the transcript)

- No explicit current capital expenditure or strategic investment details were disclosed in the call. - The company is actively pursuing 2-3 acquisition targets, focusing on emerging markets and established brand businesses to supplement portfolio growth. - Rajeev Nannapaneni mentioned a preference for acquisitions outside India due to better returns despite currency and political risks. - They currently have enough cash (approx. INR2,500 crores net) post Adcock acquisition and prefer preserving cash for large acquisitions rather than buybacks. - Financing for large acquisitions may be a mix of cash, debt, and equity depending on the size and circumstances. - There is no plan to raise capital immediately, but fundraising could be considered if a large acquisition opportunity arises. - No specific capex plans for manufacturing were detailed; FDA plant statuses were updated but no fresh investments mentioned.

- Anticipated revenue for fiscal 2026 is around INR 4,300 crores, based on Q3 and Q4 projections (Page 12). - Emerging markets (Middle East, Brazil) and Adcock profit consolidation expected to drive growth in export revenue (Page 17). - Domestic Indian market expected to grow over 20% in the next year, driven primarily by semaglutide (Page 12). - U.S. market: Several ANDA approvals and product launches, including first-to-file/shared first-to-file, expected in the next 12 months, contributing to growth (Page 16). - Base business expected to stabilize in H2 FY26; new product launches will increment growth (Page 16). - Management confident of comfortable growth over next couple of years (Page 17). - Long-term aspiration to reach ~INR 10,000 crores turnover, largely through M&A and geographic expansion (Page 10).

- For fiscal year 2026, Natco expects revenue around INR 4,300 crores and PAT between INR 1,280-1,300 crores (Page 12). - Emerging markets, including Brazil and Middle East, along with Adcock profit consolidation, are anticipated to drive future growth (Page 17). - The U.S. market is expected to see strong launches supporting growth in fiscal 2027 (Page 17). - Domestic growth in India is projected to exceed 20% mainly driven by semaglutide (Page 12). - The company maintains confidence in comfortable growth over the next couple of years, with detailed guidance expected in the May call after audited numbers (Page 17). - R&D expenditure remains prioritized for complex generics, supporting future pipeline-driven growth (Page 6). - M&A activity, especially outside India, is targeted to supplement organic growth and accelerate scale (Page 10, 17-18).

The transcript does not provide explicit details on the current or expected order book/pending orders. However, key related points include: - The company expects strong growth in the U.S. market with several ANDA approvals and product launches expected in the next 12 months, including a shared First-to-File (FTF) launch. - Emerging markets like Brazil and Middle East are showing good product launches and approvals, expected to drive export revenue growth. - Domestic market growth is largely driven by semaglutide, with a 20%+ growth target in India. - Multiple Para IV litigations and patent challenges are ongoing, impacting timelines for specific product launches. - The company is actively pursuing 2-3 large M&A targets to supplement its portfolio and geographical expansion. - R&D filings include 4-5 products this year, with 8 expected in total. No explicit order book size or pending order value was shared during the call.